Ligand Pharmaceuticals Inc

LGND has entered a Stage 3 distribution phase, with price failing at the 9 EMA and 21 EMA and a bearish Blow-Off Top pattern reinforcing supply control. Medium-term bias is bearish, and short-term momentum remains negative, favoring short entries on rallies into dynamic resistance.

• ↑Q1 total revenue hit $52M (+14% YoY) with royalty revenue at $43M (+56% YoY).
• ↑XOMA acquisition to add $0.50 EPS in 2026 and $1.50 in 2027.
• ↓Integration of over 120 ZOMA assets may delay synergies and disrupt operations.